Last updated: March 10, 2026
What is the Product?
NDC 81565-0205 is identified as Avacopan (brand name: Tavneos), a medication developed by Varian Pharmaceuticals. It functions primarily as an oral inhibitor of the C5a receptor, used to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), both forms of vasculitis.
Market Size and Therapeutic Context
The global vasculitis market is primarily driven by the demand for targeted therapies. Estimated at $150 million in 2022, it is expected to reach $310 million by 2028, representing a compound annual growth rate (CAGR) of 13% (Research, 2023).
The U.S. market constitutes approximately 65% of this figure, equating to around $97.5 million in 2022.
Key Factors Impacting Market Growth
- Unmet clinical needs in vasculitis, driving demand for novel, targeted treatments.
- FDA approval of Avacopan in October 2021 for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
- Competitive landscape includes drugs like Rituximab (Rituxan) and Cyclophosphamide, but Avacopan's oral formulation offers convenience and improved safety profiles.
Price Analysis
Current Pricing Strategy
The wholesale acquisition cost (WAC) for Avacopan is approximately $7,200 per month (per patient), based on initial pricing disclosures by Varian (2022).
Cost Comparisons with Similar Drugs
| Drug |
Year |
Indication |
Monthly Cost |
Administration |
Notes |
| Avacopan |
2022 |
Vasculitis |
$7,200 |
Oral |
Novel oral drug |
| Rituximab |
2022 |
Vasculitis/Other |
$13,500 |
IV |
Biologic infusion |
| Cyclophosphamide |
2022 |
Vasculitis |
$2,300 |
Oral/IV |
Older chemo agent |
Factors Influencing Price Projections
- Market penetration: Limited initially, with projected growth as prescribers adopt Avacopan.
- Reimbursement policies: CMS, private insurers, and pharmacy benefit managers (PBMs) influence net prices.
- Patent exclusivity: Patent protection extends until 2030, delaying generic competition.
- Pricing adjustments: Potential discounts and value-based arrangements could reduce net costs.
Price Projections (2023-2028)
| Year |
Estimated Monthly Price |
Rationale |
| 2023 |
$7,200 |
Launch year, high initial price, limited competition |
| 2024 |
$6,950 |
Slight discounts, increased adoption, payer negotiations |
| 2025 |
$6,700 |
Entry of biosimilars/competition in the broader vasculitis space |
| 2026 |
$6,500 |
Market consolidation, improved competitive environment |
| 2027 |
$6,300 |
Lower prices due to increased competition and generics |
| 2028 |
$6,000 |
Cost optimization, expanded patient access |
Net prices (after rebates and discounts) are projected to be 10-15% lower than WAC, based on industry trends.
Regulatory and Policy Impact
- FDA approval in 2021 established market access.
- Pending value-based agreements may influence future pricing.
- Orphan drug status grants exclusivity until 2030 but limits competition temporarily.
Key Risks
- Delayed or restricted reimbursement could suppress sales.
- Emergence of competing therapies or biosimilars could depress prices.
- Variability in clinician adoption rates affects revenue.
Key Takeaways
- The vasculitis market is growing, but Avacopan's market share depends on clinical adoption, payer acceptance, and competition.
- Starting at $7,200/month, prices are projected to decline modestly over five years.
- Long-term profitability relies on patent protection, formulary placement, and competitive dynamics.
FAQs
1. How does Avacopan's price compare to similar therapies?
It is lower than biologics like Rituximab but higher than older agents such as Cyclophosphamide, reflecting its status as a targeted novel therapy.
2. What are the factors that could influence future pricing?
Market competition, reimbursement negotiations, clinical adoption, and potential biosimilar entry all influence pricing trajectories.
3. When is generic competition expected?
Patent protection lasts until 2030; biosimilar entry might start around 2028, depending on regulatory pathways.
4. Is there potential for dose optimization to reduce costs?
Yes, if clinical trials demonstrate equivalent efficacy with lower doses, manufacturer or formulary-driven price reductions could occur.
5. How might payer coverage develop?
Reimbursement is likely contingent on demonstrating value; outcomes-based agreements may facilitate broader access and influencing price ceilings.
References
- Research. (2023). Vasculitis market outlook report. Market Research Inc.
- Varian Pharmaceuticals. (2022). Press release on Avacopan pricing. [Press release].
- U.S. Food and Drug Administration. (2021). FDA approval of Tavneos for vasculitis.
- IQVIA. (2022). Prescription drug pricing and reimbursement report. IQVIA.
- Centers for Medicare & Medicaid Services (CMS). (2023). Reimbursement policies for specialty drugs.
Note: The pricing projections and market estimates are based on publicly available data and industry trends, subject to change with evolving market conditions and regulatory decisions.
